If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-07. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
=== Difficulties === Hyperthymestic abilities can have a detrimental effect. The constant, irrepressible stream of memories has caused significant disruption to Price's life. She described her recollection as "non-stop, uncontrollable and totally exhausting" and as "a burden". Price is prone to getting lost in remembering. This can make it difficult to attend to the present or future, as she is often spending time re-living the past. Price displays considerable difficulty in memorising allocentric information. According to James McGaugh, "Her autobiographical memory, while incredible, is also selective and even ordinary in some respects". This was demonstrated by her having poor performance on standardised memory tests and average performance at school, unable to apply her exceptional memory to her studies. Deficits in executive functioning and anomalous lateralisation were also identified in Price. These cognitive deficiencies are characteristic of frontostriatal disorders. Even those with a high level of hyperthymesia do not remember exactly everything in their lives or have "perfect memory". Studies have shown that it is a selective ability, as shown by Price's case, and they can have comparative difficulty with rote memorisation and therefore cannot apply their ability to school and work. Their memorisation of events tends to exceed their ability to memorise given facts; for example, if a hyperthymesiac were told a fact, he might forget the fact even while remembering the teller's clothing and other aspects of the situation, making the memories even more potent.
WALP peptides are a class of synthesized, membrane-spanning α-helices composed of tryptophan (W), alanine (A), and leucine (L) amino acids. They are designed to study properties of proteins in lipid membranes such as orientation, extent of insertion, and hydrophobic mismatch.
The two-fold purpose of the double-lumen technology was: (i) the aesthetic benefits of silicone gel (contained in the inner lumen) that is enclosed within the outer lumen, which is filled with saline solution; and (ii) a breast prosthesis whose volume is post-operatively adjustable. In surgical practise, the double-lumen prosthetic breast is used primarily in reconstructive surgery of the breasts.
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}[][a_{0},a_{1},a_{2},a_{3}]&=[0.5,0.182536384941,0.039812283118,0.003684879001]\\[][b_{1},b_{2},b_{3},b_{4},b_{5},b_{6}]&=[1.960841785003,1.708677456715,0.856592986083,0.264996791567,0.049257843893,0.004640740133]\end{aligned}}}
=== Tissue regeneration === Work with cell cultures and experiments with animals have shown that administration of thymosin β4 can promote migration of cells, formation of blood vessels, maturation of stem cells, survival of various cell types and lowering of the production of pro-inflammatory cytokines. These multiple properties have provided the impetus for a worldwide series of on-going clinical trials of potential effectiveness of thymosin β4 in promoting repair of wounds in skin, cornea and heart. Such tissue-regenerating properties of thymosin β4 may ultimately contribute to repair of human heart muscle damaged by heart disease and heart attack. In mice, administration of thymosin β4 has been shown to stimulate formation of new heart muscle cells from otherwise inactive precursor cells present in the outer lining of adult hearts, to induce migration of these cells into heart muscle and recruit new blood vessels within the muscle.
ketamine (K; Ketalar, Ketaset, Ketanest; "Ket", "Kit Kat", "Special-K", "Vitamin K", "Jet Fuel", "Horse Tranquilizer") methoxetamine (Mex, Mket, Mexi) phencyclidine (PCP; Sernyl; "Angel Dust", "Rocket Fuel", "Sherm", "Killer Weed", "Super Grass") nitrous oxide (N2O; "NOS", "Laughing Gas", "Whippets", "Balloons") Psychedelics Phenethylamines 2C-B ("Nexus", "Venus", "Eros", "Bees") 2C-E ("Eternity", "Hummingbird") 2C-I ("Infinity") 2C-T-2 ("Rosy") 2C-T-7 ("Blue Mystic", "Lucky 7") DOB DOC DOI DOM ("Serenity, Tranquility, and Peace" ("STP")) MDMA ("Ecstasy", "E", "Molly", "Mandy", "MD", "Crystal Love") mescaline (found in peyote and Trichocereus macrogonus (Peruvian torch, San Pedro cactus, Echinopsis langeniformis)) Tryptamines (including ergolines and lysergamides) 5-MeO-DiPT ("Foxy", "Foxy Methoxy") 5-MeO-DMT (found in various plants like chacruna, jurema, vilca, and yopo) α-methyltryptamine (αMT; Indopan; "Spirals") bufotenin (secreted by Bufo alvarius, also found in various Amanita mushrooms) dimethyltryptamine (DMT; "Dimitri", "Disneyland", "Spice"; found in large amounts in Psychotria and in D. cabrerana) lysergic acid amide (LSA; ergine; found in morning glory and Hawaiian baby woodrose seeds) lysergic acid diethylamide (LSD; L; Delysid; "Acid", "Sid".
== Sources == This article incorporates text from a free content work. Licensed under Cc BY-SA 3.0 IGO (license statement/permission). Text taken from Drowning in Plastics – Marine Litter and Plastic Waste Vital Graphics, United Nations Environment Programme.
Sources: en.wikipedia.org
== Interaction with integrin α2β1 == Cellular receptors for collagens belong to the family of β1 integrins. Collagen XXIII interacts in an ion-and conformation-dependent manner with integrin α2β1. Integrin α2β1 is a collagen-binding integrin present at the epidermis, therefore this is the location where the interaction takes place. Both proteins co-localize on basal keratinocytes surface.
== Resistance == When Alexander Fleming discovered the crude penicillin in 1928, one important observation he made was that many bacteria were not affected by penicillin. This phenomenon was realised by Ernst Chain and Edward Abraham while trying to identify the exact mechanism of penicillin. In 1940, they discovered that unsusceptible bacteria like Escherichia coli produced specific enzymes that can break down penicillin molecules, thus making them resistant to the antibiotic. They named the enzyme penicillinase. Penicillinase is now classified as member of enzymes called β-lactamases. These β-lactamases are naturally present in many other bacteria, and many bacteria produce them upon constant exposure to antibiotics. In most bacteria, resistance can be through three different mechanisms – reduced permeability in bacteria, reduced binding affinity of the penicillin-binding proteins (PBPs) or destruction of the antibiotic through the expression of β-lactamase. Using any of these, bacteria commonly develop resistance to different antibiotics, a phenomenon called multi-drug resistance. The actual process of resistance mechanism can be very complex. In case of reduced permeability in bacteria, the mechanisms are different between gram-positive and gram-negative bacteria. In gram-positive bacteria, blockage of penicillin is due to changes in the cell wall. For example, resistance to vancomycin in S. aureus is due to additional peptidoglycan synthesis that makes the cell wall much thicker preventing effective penicillin entry.
Among her appointments are James Cleverly, who becomes Shadow Housing Secretary. Welsh Conservative member of the Senedd Laura Anne Jones joins Reform UK. 19-year-old George Finch is formally appointed as leader of Warwickshire County Council, making the Reform UK councillor the UK's youngest permanent council leader. 23 July – The Scottish Greens are forced to issue a new list of candidates for the next Holyrood election after an error was found in counting the votes. 24 July – Jeremy Corbyn and Zarah Sultana officially launch their new political party, which has the provisional name Your Party. 25 July – 220 MPs sign a letter to the prime minister urging him to recognise Palestinian statehood. Former SNP MP Mhairi Black announces that she has left the party, citing its stance over transgender rights and Palestine as her main reasons for doing so. US President Donald Trump arrives at Prestwick Airport to begin a four-day private visit to the United Kingdom during which he will meet Prime Minister Keir Starmer and First Minister of Scotland John Swinney. 29 July – Starmer announces the UK will recognise a Palestinian state in September unless Israel takes "substantive steps to end the appalling situation in Gaza". Benjamin Netanyahu, Israel's prime minister, says in response that to do so "rewards Hamas's monstrous terrorism". Ghazi Hamad of Hamas welcomes the announcement as "one of the fruits of October 7". Trump completes his four-day visit to Scotland and returns to the United States.
{\displaystyle {\begin{aligned}\log K_{{\text{assoc}},1}&=\mathrm {p} K_{{\text{dissoc}},3}\\\log K_{{\text{assoc}},2}&=\mathrm {p} K_{{\text{dissoc}},2}\\\log K_{{\text{assoc}},3}&=\mathrm {p} K_{{\text{dissoc}},1}\end{aligned}}}
Andrew went into business with his father in the United States in 1973, opening their first Panda Inn restaurant in Pasadena, California. At the beginning, business was lacking to the degree that Andrew had to offer special deals and freebies so that customers would dine at Panda Inn. In 1982, Peggy joined Andrew in the restaurant business. While operating Panda Inn, Andrew became acquainted with then-UCLA head football coach Terry Donahue, as well as Terry's brother Dan, who happened to be in the real estate business. It was because of this connection that in 1983, Donahue Schriber Real Estate, the manager of the Glendale Galleria, invited the Cherngs to develop a fast-food version of Panda Inn for the Galleria's food court, and Panda Express was launched that October. A second location was opened two years later at the Westside Pavilion in 1985. The chain has steadily expanded across the United States since then. Chef Andy Kao claims to have developed the original Chinese-American orange chicken recipe at a Panda Express in Hawaii in 1987.At first, Panda Express restaurants were found solely in food courts in major shopping malls. During the late 1980s and early 1990s, the Cherngs began experimenting with supermarket-based branches, through a deal with Vons, and then stand-alone restaurant locations. In 1997, the company opened its first stand-alone, drive-through restaurant, in Hesperia, California. Today less than 2% of its restaurants are in malls.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.